This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Study of Alternating Sunitinib and Temsirolimus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2015 by Lionel.D.Lewis, MD, Dartmouth-Hitchcock Medical Center.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Lionel.D.Lewis, MD, Dartmouth-Hitchcock Medical Center Identifier:
First received: January 17, 2012
Last updated: May 31, 2016
Last verified: August 2015
In the past 5 years, treatment for metastatic Renal Cell Carcinoma (mRCC) has focused on agents directed at blocking tumor and vascular growth pathways. Sunitinib blocks the vascular endothelial growth factor receptor (VEGFr) and temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR). Both sunitinib and temsirolimus are FDA approved agents for mRCC. When agents like these are given together, the toxicity increases but they can be given safely, at full doses, sequentially. We hypothesize that alternating these agents will double the progression free survival (PFS) of the agents when given sequentially.

Condition Intervention Phase
Metastatic Renal Cell Carcinoma Drug: Sunitinib Drug: Temsirolimus Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus

Resource links provided by NLM:

Further study details as provided by Lionel.D.Lewis, MD, Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • Time to Progression [ Time Frame: From the date of randomization until the first documented progression or date of death from any cause. ]
    To determine the time to progression in metastatic renal cell carcinoma patients treated with alternating targeted therapy

Secondary Outcome Measures:
  • Clinical Response Rate [ Time Frame: Every 12 weeks until progression, estimated time frame is 18 months ]
    To be assigned a status of partial response or complete response, changes in tumor measurements must be confirmed by repeat assessments that should be performed no less than 4 weeks after the criteria for response are first met. In the case of stable disease, follow-up measurements must have met the stable disease criteria at least once after study entry at a minimum interval (in general, not less than 6-8 weeks) that is defined in the study protocol.

Estimated Enrollment: 37
Study Start Date: June 2010
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alternating Sunitinib and Temsirolimus

A cycle is defined as:

Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest

Drug: Sunitinib
Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
Other Name: Sutent
Drug: Temsirolimus
Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
Other Name: TORISEL®

Detailed Description:

SUMMARY: Alternating Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus

Patients with measurable metastatic renal cell carcinoma (any histology) are eligible. All patients will be treated as outlined below with sunitinib alternating with temsirolimus.

Patients will be treated continuously, until evidence of progression of disease, or for up to two cycles following disappearance of all disease.

A cycle is defined as:

Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Histologically confirmed metastatic renal cell cancer with evaluable disease.
  • Patients must be at least 2 weeks from their last immunotherapy, surgery or chemotherapy (6 weeks for nitrosureas) and recovered from all ill effects.
  • Karnofsky Performance Status ≥60%
  • Life expectancy ≥ twelve weeks
  • Adequate end organ function:

Cardiac Left ventricular ejection fraction (LVEF) ≥lower limit of institutional normal (LLN) as assessed by echocardiography (ECHO) . The same modality used at baseline must be applied for subsequent evaluations.

  • Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study and practicing acceptable forms of birth control
  • Appropriate Contraception in both sexes
  • The patient must be competent and signed informed consent.


  • Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence, breast CIS.
  • In patients with a prior history of invasive malignancy, less than five years in complete remission.
  • Have evidence of significant co-morbid illness such as uncontrolled diabetes, hypertension or active infection that would preclude treatment on this regimen.
  • Prior treatment with either sunitinib or temsirolimus
  • Clinically significant gastrointestinal abnormalities
  • Presence of uncontrolled infection.
  • Prolongation of corrected QT interval (QTc) > 480 milliseconds - History of any one or more of the following cardiovascular conditions within the past 12 months:

    1. Cardiac angioplasty or stenting
    2. Myocardial infarction
    3. Unstable angina
    4. Coronary artery by-pass graft surgery
    5. Symptomatic peripheral vascular disease
    6. Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
  • History of cerebrovascular accident (CVA) including transient ischemic attack (TIA) within the past 12 months.
  • History of pulmonary embolism or untreated deep venous thrombosis (DVT)within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anticoagulating agents for at least 6 weeks are eligible.
  • Poorly controlled hypertension [defined as systolic blood pressure (SBP) of

    ≥150 or diastolic blood pressure (DBP) of ≥ 90. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry.

  • Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
  • Evidence of active bleeding or bleeding diathesis
  • Hemoptysis within 6 weeks of first dose of study drug.
  • Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
  • Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study.
  • Is now undergoing and/or has undergone in the 14 days immediately prior to first dose of study drug any minor surgeries (i.e. skin biopsy, tooth extraction, etc.) and recovered from all ill effects.
  • Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity.
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to sunitinib or temsirolimus.
  • Untreated brain metastasis. (Brain metastases that are stable based on radiographic evidence 4 weeks after radiation and/or surgery are permitted).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01517243

United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, Vermont
University of Vermont, Vermont Cancer Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Principal Investigator: Lionel D Lewis, MD Dartmouth-Hitchcock Medical Center
  More Information

Additional Information:
Responsible Party: Lionel.D.Lewis, MD, Medical Director of the Dartmouth Clinical Trials Office, Dartmouth-Hitchcock Medical Center Identifier: NCT01517243     History of Changes
Other Study ID Numbers: D1011
Study First Received: January 17, 2012
Last Updated: May 31, 2016

Keywords provided by Lionel.D.Lewis, MD, Dartmouth-Hitchcock Medical Center:
Metastatic Renal Cell Carcinoma

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Immunosuppressive Agents
Immunologic Factors
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on September 21, 2017